Journal
BIOCHEMISTRY
Volume 43, Issue 51, Pages 16461-16466Publisher
AMER CHEMICAL SOC
DOI: 10.1021/bi048075t
Keywords
-
Categories
Funding
- NIGMS NIH HHS [GM54469] Funding Source: Medline
Ask authors/readers for more resources
The toll that Streptococcus pneumoniae exacts on the welfare of humanity is enormous. This organism claims the lives of similar to3700 people daily, the majority of whom are children below the age of 5, and the situation could worsen due to the increasing incidence of pernicious, multiple-antibiotic-resistant strains. Here we report the discovery and characterization of a new allosteric site, shown to be absent in humans, that can be used to switch off an essential pathway in S. pneumoniae, the mevalonate pathway. Diphosphomevalonate (DPM), an intermediate in the pathway, binds with high affinity (K-d = 530 nM) to mevalonate kinase, the first enzyme in the pathway, and inactivates it. Steady-state and equilibrium binding measurements reveal that DPM binding is noncompetitive versus substrates. DPM binds at an allosteric site, and inhibition cannot be overcome by an increasing substrate concentration. The DPM-binding site is a promising target for the development of new antimicrobial agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available